607 related articles for article (PubMed ID: 16945449)
1. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
Andersson K; Bergström G; Petzold MG; Carlsten A
Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
[TBL] [Abstract][Full Text] [Related]
2. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
[TBL] [Abstract][Full Text] [Related]
3. Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals?
Granlund D
Soc Sci Med; 2009 Dec; 69(11):1643-50. PubMed ID: 19815322
[TBL] [Abstract][Full Text] [Related]
4. Physicians' opinions and experiences of the Pharmaceutical Benefits Reform.
Andersson K; Jörgensen T; Carlsten A
Scand J Public Health; 2006; 34(6):654-9. PubMed ID: 17132599
[TBL] [Abstract][Full Text] [Related]
5. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden.
Andersson K; Sonesson C; Petzold M; Carlsten A; Lönnroth K
Pharmacoepidemiol Drug Saf; 2005 May; 14(5):341-8. PubMed ID: 15624198
[TBL] [Abstract][Full Text] [Related]
6. Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years.
Andersson KA; Petzold MG; Allebeck P; Carlsten A
BMC Health Serv Res; 2008 Feb; 8():50. PubMed ID: 18312635
[TBL] [Abstract][Full Text] [Related]
7. Price and welfare effects of a pharmaceutical substitution reform.
Granlund D
J Health Econ; 2010 Dec; 29(6):856-65. PubMed ID: 20832130
[TBL] [Abstract][Full Text] [Related]
8. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
Usher C; Tilson L; Bennett K; Barry M
Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
10. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.
Tilson L; Bennett K; Barry M
Eur J Health Econ; 2005 Sep; 6(3):267-73. PubMed ID: 15977036
[TBL] [Abstract][Full Text] [Related]
11. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
12. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical insurance and the demand for prescription pharmaceuticals in Västerbotten, Sweden.
Rudholm N
Scand J Public Health; 2005; 33(1):50-6. PubMed ID: 15764241
[TBL] [Abstract][Full Text] [Related]
14. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
[TBL] [Abstract][Full Text] [Related]
15. Public drug expenditure in the Republic of Ireland.
Barry M; Usher C; Tilson L
Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
[TBL] [Abstract][Full Text] [Related]
16. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
[TBL] [Abstract][Full Text] [Related]
17. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
Lee IH; Bloor K; Hewitt C; Maynard A
Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
[TBL] [Abstract][Full Text] [Related]
18. Projecting future drug expenditures--1994.
Santell JP
Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
[TBL] [Abstract][Full Text] [Related]
19. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
Tilson L; McGowan B; Ryan M; Barry M
Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical expenditure in Sweden.
Henriksson F; Hjortsberg C; Rehnberg C
Health Policy; 1999 May; 47(2):125-44. PubMed ID: 10538288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
